3.26  0.11 (3.49%)		05-13 13:51
Open: 3.15 High: 3.34 Volume: 42,155		Pre. Close: 3.15 Low: 3.145 Market Cap: 2(M)

Short term
Mid term
Targets	6-month :	4.16	1-year :	4.6
Resists	First :	3.56	Second :	3.94
Pivot price	3.26
Supports	First :	2.97	Second :	2.47
MAs	MA(5) :	3.18	MA(20) :	3.32
	MA(100) :	3.59	MA(250) :	5.78
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	18.7	D(3) :	9.5
RSI	RSI(14): 51.6
52-week	High :	12.02	Low :	2.33

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ ACON ] has closed below upper band by 32.5%. Bollinger Bands are 76.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 41 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	3.19 - 3.21	3.21 - 3.22
Low:	2.99 - 3.01	3.01 - 3.03
Close:	3.12 - 3.15	3.15 - 3.17

Aclarion, Inc., a healthcare technology company, develops software application for magnetic resonance spectroscopy (MRS) in the United States. It offers NOCISCAN-LS Post-Processor suite comprising NOCICALC-LS that receives and processes the acquired disc MRS data to calculate levels of degenerative pain biomarkers; and NOCIGRAM-LS, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was founded in 2008 and is based in San Mateo, California.

Tue, 12 May 2026
Aclarion director Scott Breidbart acquires $18,011 in stock - Investing.com

Tue, 12 May 2026
Director at Aclarion (ACON) buys 5,664 Common Stock shares in public trade - Stock Titan

Tue, 12 May 2026
Aclarion director David Neal buys $7,750 in company stock - Investing.com

Tue, 12 May 2026
Aclarion (NASDAQ: ACON) director purchases 2,500 shares in open market trade - Stock Titan

Mon, 11 May 2026
Aclarion (ACON) CEO makes open-market share purchase - Stock Titan

Fri, 08 May 2026
Aclarion (ACON) director adds 1,562 shares in open-market purchase - Stock Titan

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Medical - Healthcare Information Services
Shares Out	0 (M)
Shares Float	2 (M)
Held by Insiders	2.04e+006 (%)
Held by Institutions	9.9 (%)
Shares Short	143 (K)
Shares Short P.Month	0 (K)

EPS	-6.82e+006
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	-10 %
Return on Assets (ttm)	785.1 %
Return on Equity (ttm)	-55.9 %
Qtrly Rev. Growth	75730 %
Gross Profit (p.s.)	71.32
Sales Per Share	-92.75
EBITDA (p.s.)	6044.24
Qtrly Earnings Growth	-13.7 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	-7 (M)

PE Ratio	-0.01
PEG Ratio	0
Price to Book value	0
Price to Sales	-0.04
Price to Cash Flow	0.25

Dividend	0
Forward Dividend	197720
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.